Y L Xu

1PUBLICATIONS
0CO-AUTHORS
Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|May 12, 2017
FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer.

Y L Xu, R Yao, J Li

Pageof 1

Frequent Collaborators